Gt Biopharma Stock Analysis

GTBP Stock Analysis Notes

About 12.0% of the company shares are held by company insiders. The book value of GT Biopharma was currently reported as 5.41. The company recorded a loss per share of 7.39. GT Biopharma last dividend was issued on the 21st of August 2017. The entity had 1:30 split on the 5th of February 2024. GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager fusion protein immune cell engager technology platform. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. GT Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To learn more about GT Biopharma call the company at 415 919 4040 or check out https://www.gtbiopharma.com.

GT Biopharma Investment Alerts

GT Biopharma Upcoming and Recent Events

GTBP Largest EPS Surprises

View All Earnings Estimates

GT Biopharma Environmental, Social, and Governance (ESG) Scores

GTBP Stock Institutional Investors

Note, although GT Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

GTBP Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.39 M.

GTBP Profitablity

Management Efficiency

GT Biopharma has return on total asset (ROA) of (0.6059) % which means that it has lost $0.6059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3148) %, meaning that it created substantial loss on money invested by shareholders. GT Biopharma's management efficiency ratios could be used to measure how well GT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -1.91. At this time, GT Biopharma's Total Current Liabilities is relatively stable compared to the past year. As of 11/28/2024, Change To Liabilities is likely to grow to about 8.5 M, while Liabilities And Stockholders Equity is likely to drop slightly above 13.2 M.

Technical Drivers

As of the 28th of November, GT Biopharma owns the Standard Deviation of 4.75, semi deviation of 4.16, and Market Risk Adjusted Performance of 0.7281. GT Biopharma technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.

GT Biopharma Price Movement Analysis

GT Biopharma Insider Trading Activities

GT Biopharma Outstanding Bonds

GT Biopharma Predictive Daily Indicators

GT Biopharma Corporate Filings

GT Biopharma Forecast Models

GT Biopharma's time-series forecasting models are one of many GT Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GT Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how GT Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GTBP shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GT Biopharma. By using and applying GTBP Stock analysis, traders can create a robust methodology for identifying GTBP entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GTBP analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GTBP analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

GT Biopharma stock analysis indicators help investors evaluate how GT Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GT Biopharma shares will generate the highest return on investment. By understating and applying GT Biopharma stock analysis, traders can identify GT Biopharma position entry and exit signals to maximize returns.

When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.